Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication
Abstract
Objective: The purpose of this study was to examine the risk assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication.
Material & Method: In the present study total 30 patient with essential hypertension of both sex with mean age (48.6±0.8313) were recruited as per the inclusion criteria. Patients were segregated on the behalf of therapy they were using. 22 patients were on Losartan+HCTZ therapy and 8 patients were on Atenolol therapy.
Result: After six month of antihypertensive therapy Atenolol group showing a significant difference in their blood glucose (0.0014) whereas in Losartan+HCTZ group significant difference was not observed (0.1542). Patients of Atenolol group when compared with patient of Losartan+HCTZ group a significant difference was observed in the serum cholesterol level (0.0290).
Conclusion: We found that the use of β-blocker was independently associated with increased risk of type 2 diabetes. So increase in blood glucose in the Atenolol group patient revealed a significant association between use of Atenolol therapy and metabolic dysfunction whereas in Losartan+HCTZ group significant increase in blood glucose was not observed and from these we can conclude therapy with Losartan+HCTZ therapy not associated with metabolic dysfunction.
References
2. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995; 13: 1457-1462 [PMID: 8866908]
3. Lender D, Arauz-Pacheco C, Adams-Huet B, Raskin P. Essential hypertension is associated with decreased insulin clearance and insulin resistance. Hypertension 1997; 29:111-114 [PMID: 9039089]
4. Todd W. Gress, Javier Nieto, Eyal Shahar et al, “Hypertension And Antihypertensive Therapy As Risk Factors For Type 2 Diabetes Mellitus”, The New England J Of Medicine, 2000, 342, 908-917.
5. Christos V Rizos, Moses S Elisaf, “Antihypertensive drugs and glucose metabolism” World J Cardiol 2014 July 26; 6(7): 517-530 ISSN 1949-8462
6. Padwal R, Laupacis A: Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004, 27:247–255.
7. Eric N Taylor, Frank B. Hu, Gary C. Curhan, “Antihypertensive medications and the risk of incident type 2 diabetes”, cardiovascular and metabolic risk, Diabetes Care, May 2006, Volume 29, Number 5, 1065-1070
